```html

Clostridioides difficile Infection (CDI) – A Complete Patient Guide

Overview

Clostridioides difficile (formerly *Clostridium difficile*) is a Gram‑positive, spore‑forming anaerobic bacterium that can cause inflammation of the colon, known as colitis. When the bacteria release toxins A and B, they damage the intestinal lining, leading to a spectrum of disease ranging from mild diarrhea to life‑threatening colitis.

Although anyone can acquire CDI, it most commonly affects:

• Adults > 65 years old
• People who have recently taken broad‑spectrum antibiotics
• Patients in hospitals, nursing homes, or long‑term care facilities
• Individuals with weakened immune systems (e.g., chemotherapy, HIV)

**Prevalence** – In the United States, CDI accounts for about 462,000 infections and 29,000 deaths each year (CDC, 2023). Worldwide, incidence varies from 1–5 cases per 1,000 hospital admissions, with higher rates in North America and Europe.

Symptoms

Symptoms usually appear 5–10 days after antibiotic exposure but can develop earlier or later. The severity can be categorized as mild, moderate, severe, or fulminant.

• Watery diarrhea – ≥3 loose stools in 24 hours (most common symptom).
• Abdominal cramping or pain – often in the lower abdomen.
• Fever – usually low‑grade (<38 °C) but may be higher in severe disease.
• Loss of appetite and nausea.
• Dehydration – dry mouth, dizziness, reduced urine output.
• Blood or mucus in stool – suggests more severe colitis.
• Elevated white‑blood‑cell count (WBC) – laboratory finding often >15,000 cells/µL in severe cases.
• Severe abdominal distention, tenderness, or guarding – may indicate fulminant colitis.
• Systemic signs – rapid heart rate, low blood pressure, confusion (especially in older adults).

Causes and Risk Factors

What causes CDI?

CDI occurs when the normal gut flora is disrupted, allowing C. difficile spores to germinate and proliferate. The bacteria produce two potent exotoxins (toxin A and toxin B) that inflame the colon and cause mucus secretion, fluid loss, and cellular death.

Key risk factors

• Antibiotic use – especially clindamycin, fluoroquinolones, cephalosporins, and broad‑spectrum penicillins.
• Hospitalization or long‑term care stay – close proximity to other infected patients and frequent antibiotic exposure.
• Age ≥ 65 years – immune senescence and comorbidities increase vulnerability.
• Immunosuppression – chemotherapy, corticosteroids, solid‑organ transplantation, HIV/AIDS.
• Previous CDI – recurrence risk up to 20‑30 % after the first episode.
• Gastrointestinal surgery or severe underlying GI disease – especially inflammatory bowel disease.
• Proton‑pump inhibitor (PPI) use – may alter gastric acidity and gut microbiome.
• Residence in a community with high CDI prevalence – spores can persist on surfaces for months.

Diagnosis

Prompt and accurate diagnosis is essential because untreated CDI can progress rapidly.

Clinical assessment

• History of recent antibiotic use, hospitalization, or contact with a CDI case.
• Documented ≥3 unformed stools in 24 hours.
• Evaluation for signs of severity (fever, leukocytosis, creatinine rise, hypotension).

Laboratory tests

1. Stool toxin PCR or NAA (nucleic acid amplification test) – most sensitive and widely used.
2. Enzyme immunoassay (EIA) for toxin A/B – rapid (≤2 hours) but less sensitive; often combined with GDH (glutamate dehydrogenase) antigen testing.
3. Culture – rarely needed for routine care; used for outbreak investigation.
4. Complete blood count (CBC) – leukocytosis suggests severe disease.
5. Serum creatinine – rise ≥1.5 times baseline indicates severe infection.
6. Imaging (CT abdomen/pelvis) – may show colonic wall thickening, “accordion sign,” or megacolon in fulminant cases.

According to the Infectious Diseases Society of America (IDSA) and the American College of Gastroenterology (ACG), testing should be performed only on patients with clinically significant diarrhea to avoid false‑positive results from colonization.

Treatment Options

Treatment goals are to eradicate the organism, halt toxin production, and restore a healthy gut microbiome.

First‑line antibiotics (2023‑2024 guidelines)

• Vancomycin 125 mg PO q6h for 10 days – preferred for initial episode.
• Fidaxomicin 200 mg PO q12h for 10 days – comparable efficacy, lower recurrence risk, but higher cost.

If the patient cannot tolerate oral therapy, rectal vancomycin (500 mg in 100 mL saline administered via enema) may be used.

Recurrent CDI

• Fidaxomicin (extended regimen) or vancomycin pulsed‑taper (125 mg PO daily for 10 days, then every 2‑3 days for 2‑8 weeks).
• Bezlotoxumab – a monoclonal antibody given as a single IV infusion (10 mg/kg) alongside antibiotics to neutralize toxin B and reduce recurrence.
• Fecal microbiota transplantation (FMT) – highly effective (>85 % cure) for ≥2 recurrences; delivered via colonoscopy, enema, or oral capsules.

Supportive care

• Aggressive rehydration – oral rehydration solutions or IV fluids for severe dehydration.
• Electrolyte monitoring (especially potassium and magnesium).
• Temporary discontinuation of the inciting antibiotic, if feasible.
• Analgesia with acetaminophen (avoid NSAIDs that may increase GI bleeding risk).

Surgical intervention

Fulminant colitis with perforation, toxic megacolon, or refractory shock may require emergent colectomy (subtotal colectomy with end ileostomy). Surgery is now reserved for <5 % of cases but carries a high mortality (>30 %).

Living with Clostridioides difficile Infection

Daily management tips

• Hydration – aim for at least 2 L of fluid per day (water, broths, oral rehydration solutions). Add a pinch of salt and a teaspoon of sugar if you develop diarrhea.
• Diet – low‑fiber, bland foods (BRAT diet: bananas, rice, applesauce, toast) during acute phase; gradually reintroduce fiber as tolerated.
• Probiotics – evidence is mixed; some studies suggest Saccharomyces boulardii may reduce recurrence when used with antibiotics. Discuss with your clinician before starting.
• Medication adherence – complete the full course, even if you feel better.
• Hygiene – wash hands with soap and water (alcohol rubs do not kill spores). Clean bathroom surfaces with a bleach‑based disinfectant (10 % sodium hypochlorite).
• Activity – rest during the acute phase; light walking can help prevent deconditioning.
• Follow‑up – schedule a clinic visit 1–2 weeks after finishing therapy to ensure symptom resolution.

Emotional & social considerations

CDI can be isolating, especially in hospital settings. Ask your care team about visitor policies, and let friends/family know you’re taking steps to prevent spread. Support groups (online or local) can provide reassurance.

Prevention

• Antibiotic stewardship – only use antibiotics when prescribed, and choose the narrowest effective agent.
• Hand hygiene – wash hands with soap and water for at least 20 seconds after using the restroom.
• Environmental cleaning – hospitals and long‑term care facilities should use sporicidal agents (bleach, hydrogen peroxide vapor) on high‑touch surfaces.
• Isolation precautions – patients with suspected/confirmed CDI should be placed in a private room with contact precautions.
• Vaccines – several candidate vaccines are in Phase III trials (e.g., Pfizer’s rVA‑CD). No vaccine is currently approved.
• Probiotic prophylaxis – not routinely recommended, but high‑risk patients (e.g., on prolonged antibiotics) may discuss this with a provider.
• Limit PPI use – use the lowest effective dose for the shortest duration.

Complications

If CDI is not promptly treated, it can lead to serious outcomes:

• Toxic megacolon – massive dilation of the colon; risk of perforation.
• Colon perforation – peritonitis and sepsis.
• Sepsis and septic shock – high mortality, especially in older adults.
• Dehydration and acute kidney injury – from fluid loss.
• Recurrence – up to 30 % experience at least one repeat episode; each recurrence increases the risk of subsequent events.
• Long‑term bowel dysfunction – chronic diarrhea, abdominal pain, or irritable bowel syndrome–like symptoms.

When to Seek Emergency Care

References

• Centers for Disease Control and Prevention. Clostridioides difficile Infection (CDI). Updated 2023.
• Hood, M. I., et al. “Clinical Practice Guidelines for Clostridioides difficile Infection in Adults.” Infectious Diseases Society of America, 2021.
• Mayo Clinic. “C. diff infection.” 2022.
• World Health Organization. “Antimicrobial resistance.” 2022 factsheet.
• Johnson, S., & Gerding, D. “Fecal Microbiota Transplantation for Recurrent C. difficile Infection.” Cleveland Clinic Journal of Medicine, 2022.
• Rubin, D. T. et al. “Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection.” New England Journal of Medicine, 2020.

```